Brief: Acrux Ltd Receives FDA Approval For Generic Efinaconazole Solution
22/06/2021 02:34
June 22 (Reuters) - Acrux Ltd ACR.AX :
* ACRUX RECEIVES APPROVAL FROM FDA FOR ITS GENERIC VERSION
OF
JUBLIA
Source text for Eikon: ID:nASX8g3FR2
Further company coverage: ACR.AX
Recent news on Acrux
See all newsBrief: Acrux Licenses Lenzetto For Australian Market For A$5.4 Million
Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
Brief: Acrux Says Capital Gains Tax Exemptions Remain In Place For Acrux
Australia's Acrux jumps on placement to fund female testosterone program
Brief: Acrux Raises A$1.6 Mln Via At 0.95 AU Cents Per Share